Carani B Sanjeevi print  
Dr. C. B. Sanjeevi,

MD, MSc, PhD

CB.Sanjeevi, is an Associate Professor at KAROLINSKA INSTITUTE, Stockholm, Sweden. He is Head of Molecular Immunogenetics Group at the Diabetes Center Karolinska. He is also the Karolinska Institute Scientific Coordinator for India.

Dr Sanjeevi is also associated with various professional journals and associations in different capacities such as:
1. Associate Editor for Diabetologia,
2. Editor, Immunology of Diabetes series, Annals of the New York Academy of Sciences, New York,
3. Member, Council of EASD (European Association for the Study of Diabetes)
4. Editor for 'The Diabetes News',
5. Member, Editorial Board of Current Diabetes Reviews (USA).
6. Member, Editorial Board of Human Immunology
7. Member, Scientific Advisory Board of Journal of Association of Physicians of India
8. Member, Editorial Board of the Postgraduate Medical Journal

Dr Sanjeevi has 104 original papers in peer reviewed international journals in addition to 26 review articles and book chapters to his credit.

He is the recipient of prestigious awards like the
1. Prof. M.Vishwanathan Oration from RSSDI
2. Prof. Sam GP Moses Oration from RSSDI and
3. The Albert Reynolds award from EASD.
4. R.M.Shah Oration from Gujarat Diabetes Federation
5. CDRF Gold Medal Oration, Cuttack 2005
Immunogenetics of Diabetes in the Developing world
HLA DQ8 and 2 are associated with susceptibility and DQ6 to protection in Type 1 diabetes (T1DM). A set of polymorphic genes, called MHC class I chain-related genes (MIC-A) in HLA class I region interacts with NK cells. In Italians, MICA allele 5 increases the risk by 6.1 and together with susceptibility DR-DQ increases the risk several times. HLA class I genes, also identified as susceptibility genes for T1DM, interact with polymorphic Killer immunoglobulin-like receptors (KIR) on NK cells. Our results on HLA and MICA in Swedish and other populations show positive association for MICA with disease. Our results on KIR in Latvian patients with T1DM also suggest a role of KIR in the etiology of T1DM. The results from MICA and KIR studies suggest that aberrations in these genes of the innate immune system identify possible defects in the first line of defense in the etiology of T1DM. Newer studies suggest a role for these genes in the newborn screening and prediction strategies for T1DM.